PRCT

PROCEPT BioRobotics' stock has experienced several events in the past six months. In November 2025, the company reported strong third-quarter results and increased guidance, leading to "Buy" ratings from analysts. However, the stock experienced a pullback due to a fourth-quarter revenue shortfall in February 2026, despite an improved handpiece average selling price and updated 2026 revenue guidance. Positive catalysts included the international launch of the HYDROS Robotic System in March 2026 and the European Association of Urology's (EAU) upgraded recommendation for Aquablation therapy. In April 2026, first-quarter results showed a revenue increase, but the diluted loss per share widened, and full-year guidance was reaffirmed, causing investor caution. Insider trading activity and institutional investor adjustments were also noted.